Refine by
Therapeutic Potential Suppliers In Germany
6 companies found
based inLeverkusen, GERMANY
Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to help people and planet thrive by supporting efforts to address the unprecedented global challenges ...
Small molecules (SMOLs) have long been in the focus of modern medicine. Over the last century, their advent revolutionized healthcare and improved the lives of patients all over the world. Most of today´s SMOLs exert their function by binding ...
based inTuebingen, GERMANY
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation ...
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel ...
based inPlanegg, GERMANY
MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development, and delivery of innovative cancer medicines. At MorphoSys, our ambition is to redefine how cancer is treated. As a commercial-stage biopharmaceutical ...
Tafasitamab (MOR208) is a humanized FC-modified CD19 targeting immunotherapy in clinical development for the treatment of B cell malignancies. CD19 is broadly expressed on the surface of B cells. It is therefore considered as a potential target for ...
based inMalvern, PENNSYLVANIA (USA)
Since our founding in 2001, we have had one singular obsession: We strive to give our clients a personalized and collaborative research experience. We are here to help you find the answers you need to develop the best possible drug candidate for ...
ASH1L is a large , multi-domain protein associated with actively transcribed regions of chromatin, ASH1L is the human homolog of Drosophila Ash1, a Trithorax group protein. Like its counterpart in Drosophila, ASH1L contains a SET histone ...
based inMunich, GERMANY
Tubulis generates uniquely matched antibody-drug conjugates (ADCs) through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of protein-drug conjugates by ...
based inHaifa, ISRAEL
Pluristem Therapeutics Inc. is a clinical-stage regenerative medicine company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for conditions such as inflammation, muscle injuries, ...
Acute Radiation Syndrome (ARS) involves severe, potentially lethal damage to the bone marrow’s ability to produce blood cells, as well as to other systems and organs. Severe damage to bone marrow makes victims vulnerable to life-threatening ...